Analyst Price Target is $52.83
▲ +21.79% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for NeoGenomics in the last 3 months. The average price target is $52.83, with a high forecast of $65.00 and a low forecast of $14.50. The average price target represents a 21.79% upside from the last price of $43.38.
Current Consensus is
The current consensus among 9 contributing investment analysts is to buy stock in NeoGenomics. This Buy consensus rating has held steady for over two years.
NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.